Potential Drug-drug Interactions in Cancer Patients and Determination of their Risk Factors in a Third-Level Teaching Hospital

作者全名："Su, Yi; Hu, Sixing; Liu, Dong"

作者地址："[Su, Yi] Changshou Dist Maternal & Child Hlth Care Hosp Cho, Dept Pharm, Chongqing 401220, Peoples R China; [Hu, Sixing] Peoples Hosp ChangShou ChongQing, Dept Pharm, Chongqing 401220, Peoples R China; [Liu, Dong] Chongqing Med Univ, Nanchuan Peoples Hosp, Dept Pharm, Chongqing 408400, Peoples R China"

通信作者："Liu, D (通讯作者)，Chongqing Med Univ, Nanchuan Peoples Hosp, Dept Pharm, Chongqing 408400, Peoples R China."

来源：LATIN AMERICAN JOURNAL OF PHARMACY

ESI学科分类：PHARMACOLOGY & TOXICOLOGY

WOS号：WOS:000955313900022

JCR分区：Q4

影响因子：0.2

年份：2023

卷号：42

期号：3

开始页：620

结束页：626

文献类型：Article

关键词：cancer; patient safety; potential drug-drug interactions; supportive therapy

摘要：". Cancer patients often receive multiple drugs to maximize their therapeutic benefit, treat comor-bidities and counter the adverse effects of chemotherapy. Concomitant administration of multiple drugs in-creases the risk of drug interactions leading to compromised therapeutic efficacy or safety of therapy. The purpose of this study was to identify the prevalence, levels and predictors of potential drug-drug interactions (pDDIs) among cancer patients.a total of 417 patients receiving chemotherapy from a third-level hospitals were included in this cross-sectional study. Patient medication profiles were screened for pDDIs using the Drugs database. Logistic regression analysis was performed to identify the predictors of pDDIs. The overall prevalence of pDDIs was 71%, majority of patients had 1-5 pDDIs (41.49%). A total of 1858 pDDIs were detected. Moderate-pDDIs were most frequent (77.18%) .A significant association of pDDIs was found in Numbers of drugs (p < 0.001). Potential adverse outcomes of these interactions include increasing the risk of an irregular heart rhythm, Causing Parkinson-like symptoms and abnormal muscle movements, making the medication less effective in treating your cancer, drug toxicity such as muscle pains, weakness, dizziness, con-fusion were the potential adverse outcomes of these interactions. Major finding of this study is the high prev-alence of pDDIs signifying the need of strict patient monitoring for pDDIs among cancer patients. Patients at higher risk to pDDIs include those prescribed types of drugs or anticancer drugs. Moreover, list of most frequently identified major and moderate interactions will aid health care professional in timely identification and prevention of pDDIs."

基金机构：　

基金资助正文：